Moderate to Severe Ulcerative Colitis
Conditions
Brief summary
The first-line treatment strategy of moderate to severe UC was a important question at issue. The biological agents had potentiality to alter the disease course of UC. The AGA clinical guidelines had conditional recommend that IFX and other biological agene migtht be first-line therapy for high-risk UC patints but only had low grade evidence.We launched this multicenter prospective cohort trial to compare the efficacy and safety of infliximab (IFX) and corticosteroids(CS) when they was used as first-line therapy in UC patients.
Interventions
DRUGInfliximab
Infliximab was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
DRUGCorticosteroid
Corticosteroids was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
Sponsors
Sixth Affiliated Hospital, Sun Yat-sen University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* moderately to severely active ulcerative colitis, defined as a total score of 6 to 12 on the Mayo scale (scores range from 0 to 12, with higher scores indicating more severe disease) and a subscore of at least 2 on the endoscopic component of the Mayo scale (subscores on each of the four components of the Mayo scale range from 0 to 3) * Patients who had colonic involvement of at least 15 cm * Patients who had a confirmed diagnosis of ulcerative colitis at least 3 months before screening and confirmed by Pathology
Exclusion criteria
* Patients who had previously used any TNF inhibitor * Patients who were steroid-dependent or steriod-resistant * Patients who had undergone subtotal colectomy or total colectomy * Patients who had stoma
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| clinical remission | week 14 | defined as a total score of ≤2 on the Mayo scale and no subscore \>1; partial Mayo score ≤ 2, no individual subscore \> 1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| mucosal healing in induction phase | week 14 | defined as a subscore of 0 or 1 on the Mayo endoscopic component |
| histological healing in induction phase | week 14 | defined as Nancy index score of 0 |
| clinical response in maintenance phase | week 52 | defined as a reduction in the partial Mayo score \[stool frequency, rectal bleeding, and physician's global assessment\] of ≥2 points and of ≥25% from baseline, with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point |
| mucosal healing in maintenance phase | week 52 | defined as a subscore of 0 or 1 on the Mayo endoscopic component |
| clinical response in induction phase | week 14 | defined as a reduction in the partial Mayo score \[stool frequency, rectal bleeding, and physician's global assessment\] of ≥2 points and of ≥25% from baseline, with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point |
| quality of life in induction phase | week 14 | defined as an increase of ≥16 points in IBDQ score |
| quality of life in maintenance phase | week 52 | defined as an increase of ≥16 points in IBDQ score |
| adverse events | week 52 | as assessed by the incidence of adverse events |
| histological healing in maintenance phase | week 52 | defined as Nancy index score of 0 |
Countries
China
Outcome results
None listed